Status and phase
Conditions
Treatments
About
The purpose of the study is to evaluate the Efficacy and safety of Anti-PD-1 antibody combined With anlotinib in the treatment of recurrent or advanced endometrial cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
≥18 years of age and female;
Histologically confirmed diagnosis of endometrial cancer;
Patients must have received at least 1 cycle of platinum-based chemotherapy;
At least one measurable lesion according to RECIST1.1 on CT;
ECOG performance status 0-2;
Life expectancy ≥ 3 months;
Adequate hepatic, renal, heart, and hematologic functions. Absolute Neutrophil Count(ANC) ≥ 1.5×109/L, Platelet (PLT) ≥ 70×109/L, Hemoglobin(HGB) ≥ 80 g/L, total bilirubin within 1.5×the upper limit of normal (ULN), and serum transaminase≤2.5×Upper Limit Of Normal(ULN), serum creatine ≤ 1.5 x Upper Limit Of Normal(ULN), creatinine clearance rate ≥50ml/min, International Normalized Ratio<1.5 x Upper Limit Of Normal(ULN), Urinary protein≤(+)and Thyroid stimulating hormone≤ 1.5 x Upper Limit Of Normal(ULN).
Signed and dated informed consent.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
23 participants in 1 patient group
Loading...
Central trial contact
Jundong Li
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal